Safinamide mesylate CAS NO.202825-46-5

Product Name:    Safinamide mesylate
Synonyms:    (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide methanesulfonate;Safinamide mesylate;EMD 1195686 Mesylate;NW 1015;PNU 151774E;SafinaMide Methanesulfonate;PNU-151774E,FCE28073;(S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide
CAS:    202825-46-5
MF:    C17H19FN2O2.CH4O3S
MW:    398.4490232
EINECS:    
Product Categories:    Inhibitor;Inhibitors;API;chemical
Mol File:    202825-46-5.mol
 

Melting point     210° (dec)
alpha     D25 +12.9° (c = 1.1% in 98% acetic acid)
storage temp.     2-8°C
solubility     H2O: ≥15mg/mL
form     powder
color     white to tan
optical activity    [α]/D +9.5 to +14°, c = 1 (95% acetic acid)

Description    Safinamide methanesulfonate was approved in February 2015 by the EMA for the treatment of mid- to late-stage fluctuating Parkinson’s disease. This approval included use of the drug as an add-on therapy for use with levodopa, either alone or in combination with other existing therapies for Parkinson’s disease.51 Safinamide methanesulfonate, an oral α-aminoamide originally discovered by Farmitalia Carlo Erba and later developed by Newron/Zambon, functions as a highly selective and reversible inhibitor of MAO-B, leading to increased levels of dopamine and subsequent improvement in the motor symptoms of Parkinson’s disease, side effects that often result from use of other traditional treatments relying on dopamine replacement therapy.
Mechanism of action    Safinamide employs several mechanisms of action, functioning as both a dopaminergic agent through inhibition of MAO-B as well as a nondopaminergic agent via selective calcium and sodium channel modulation, leading to inhibition of glutamate release. At least one of several clinical studies of patients with mid- to late-stage Parkinson’s disease showed increased daily ON time (periods of symptom control) without accompanying motor complications (dyskinesias) upon treatment with safinamide, while studies of early stage Parkinson’s disease patients treated with this drug showed significantly improved motor symptoms during the 18-month study. Additionally, safinamide is chemically and metabolically stable, is well tolerated in patients, and has not exhibited serious adverse effects even upon treatment at higher dosage ranges.